"To Advance Meaningful Measurements"
Excerpted from Transonic Founder Cornelis Drost's Presentation At the Grand Opening Celebration, July 2012

The seeds for Transonic were planted more than 35 years ago at the NYS Veterinary College at Cornell where Transonic founder Cornelis (Cor) Drost was a senior research associate.

Working under the direction of Dr. Alan Dobson, professor of Physiology, Cor figured out how to measure the amount of blood flowing through blood vessels in a manner where one would not have to interfere with the flow inside the vessel itself.

In 1978, the group presented this theoretical breakthrough to the world. The technology used non-invasive ultrasound. Its revolutionary aspect was that it measures the actual amount of blood flowing through the vessel directly and with high accuracy, without having to do things to the vessel that would change the very flow that one would want to measure.

New technology is no good unless one can actually do something useful with it. So the mission of the Cornell group became: to Advance Meaningful Measurements. This meant that the Transonic group had to make things work in real life, with fully implanted sensors that report flows inside the animal under normal, healthy, physiological conditions.

This is where the Cornell connection was essential: many flowmeter and flowsensor designs were tested and then improved before the system, five years later, was finally ready for a larger commercial audience.

Two seminal papers from Dr. Dobson and Dr. Sellers delivered this proof to the rest of the world: Dr. Alvin Seller's paper proved that blood volume flow could be measured, under controlled conditions, in an animal study.

This validation deployed an absolute calibration technique developed by Dr. Dobson, which is, to this day, the key to Transonic's hallmark high accuracy. Another paper authored by Dr. Dobson during his sabbatical studies at Cambridge University in Great Britain delivered independent proof that the technology measured volume flow.